abstract KEYWORD INDEX signal transduction 18, 32, 35, 289, 351, 362, 370, 609, 639, 855, 868, 1196, 1412, 1416, 1471, 1478, 1501, 1514, 1529, 1535, 1718, 1725, 2127, 2275 simplified disease activity index (SDAI) 317 single item measure 2247 single nucleotide polymorphism (SNP) 730, 1280, 1584, 1587, 1972 siRNA 1450 Sirt1 knockout mice 1484 sitaxentan 565 Sj 1215, 1893, 1894, 1895, 1897, 1908, 1909, 1911, 1914, 2174 sJIA 1434 Sjogren’s syndrome 103, 495, 702, 1413, 1579, 1883, 1884, 1886, 1887, 1888, 1889, 1890, 1891, 1896, 1898, 1899, 1901, 1902, 1904, 1905, 1908, 1910, 1911, 1912, 1914, 1916, 2174, 2175, 2177, 2178 skeletal fluorosis 1568 SKG mice 1715 skin 860 skin blood flow 1220 skin fibrosis 596 skin ulcers 932 SLE indices 990 SLEDAI 462, 1437, 1878 SLEDAI-2K 772 sleep 815 sleep disorders 786, 799, 808, 820, 1228, 1406, 2071 SLICC 1881 SLICC/ACR Damage Index (SDI) 474 small fibre neuropathy 1908 small interfering RNA 2174 small molecule therapy 285 small molecules 1119, 2233 smoking 645, 661, 765, 1092, 1252, 1956, 1984, 2114 smooth muscle 1490 SNP 1608, 1885 social media 1345, 2083 social support 174, 1324, 1326, 1334, 1335, 1340, 1409 socioeconomic factors 61, 776, 790, 1221, 1460, 1463, 1553, 2140 SOCS3 1501 sodium channels 96 soluble binding domain I apoER2 1360 somatosensory 1557 sonography 889, 1626, 2225 SOST 548 spaceflight 959 spatial variation 64 specialized disease center 2077 speckle tracking echocardiography 582 sphingosine kinase 1480 spine involvement 130, 1446 splicing 348, 893 spondylarthropathy 130, 134, 223, 516, 517, 520, 522, 524, 525, 527, 528, 529, 533, 535, 540, 546, 547, 549, 550, 551, 552, 553, 558, 665, 667, 697, 761, 778, 794, 986, 1037, 1279, 1337, 1355, 1432, 1440, 1446, 1447, 1448, 1449, 1450, 1451, 1647, 1922, 1924, 1931, 1938, 1952, 1953, 1957, 1959, 1964, 1967, 1969, 1973, 1977, 1981, 1985, 2078, 2180, 2181, 2184, 2269, 2271, 2272 spondyloarthritis 665, 904, 1938, 2181 SSA/Ro 656 stable isotope labelling 843 standardisation 1781 standardized incidence ratio 398 standardized response mean 140 staphylococcus aureus 758 STAT3 370 static alignment 195 statins 72, 1028, 1056, 1677, 1833, 2255 statistical methods 577, 1564, 1585, 1586, 1588, 1942, 2079 stem cells 1473 stereology 1485 steroids 335, 445 Still’s disease 653, 701, 891, 902, 1831 stool studies 537 stress 1025 stroke 2124 strontium ranelate 1497 structural damage 1606 structural damage progression 1496 subchondral bone 192, 709, 1497 subcutaneous 396, 416, 1124, 1834, 2173 subendocardial variability ratio 1028 subset 733 sulfatase 369 SUMO 368 superantigens 267 supplementation regimens 962 suprascapular nerve block 177 surgery 1315 surgical site infections 335 surveillance 699 survey 109, 1013, 1565 survey criteria 100 survival 2018, 2022, 2037 susceptibility 255, 521, 1975, 2148, 2215 sustained remission 308, 336 Swefot trial 1392 swine influenza 697 switch 298 sympathetic nerve fibers 361 symptom management 1319 symptom modification 664 symptoms 1346 synaptotagmin VII 1374 synovial cells, synovial fluid 29, 30, 244, 352, 354, 355, 359, 362, 369, 858, 887, 1128, 1247, 1387, 1388, 1421, 1422, 1520, 1527, 1535, 1536, 1604, 1971, 1978, 2219 synovial tissue 847 synovitis 20, 32, 118, 167, 1449, 1620, 1621, 1638, 1781, 2220 synthetase syndrome 913, 930, 1377 syringe 1567 systematic analysis 143 systematic review 92, 516, 941, 952 systemic inflammation 919 systemic juvenile idiopathic arthritis 209 systemic lupus erythematosus (SLE) 1, 4, 9, 13, 24, 252, 262, 323, 422, 424, 425, 426, 427, 428, 430, 431, 432, 434, 435, 436, 437, 438, 441, 442, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 470, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 620, 625, 627, 628, 637, 656, 694, 702, 730, 731, 733, 735, 738, 740, 746, 748, 749, 750, 751, 752, 754, 757, 762, 764, 765, 769, 772, 775, 789, 790, 795, 832, 850, 857, 859, 862, 865, 990, 996, 1000, 1011, 1075, 1139, 1141, 1142, 1143, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1162, 1163, 1164, 1165, 1166, 1167, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1199, 1200, 1223, 1243, 1245, 1257, 1272, 1400, 1401, 1402, 1437, 1452, 1454, 1456, 1457, 1577, 1578, 1583, 1584, 1585, 1586, 1587, 1590, 1591, 1592, 1594, 1595, 1602, 1608, 1639, 1641, 1666, 1674, 1676, 1677, 1679, 1684, 1688, 1689, 1694, 1695, 1701, 1702, 1784, 1842, 1843, 1844, 1845, 1846, 1847, 1848, 1849, 1850, 1851, 1852, 1853, 1854, 1855, 1856, 1857, 1858, 1859, 1860, 1861, 1862, 1863, 1864, 1865, 1866, 1868, 1869, 1870, 1871, 1872, 1873, 1874, 1875, 1876, 1877, 1878, 1878, 1880, 1881, 1882, 1895, 1909, 2070, 2077, 2083, 2106, 2113, 2120, 2122, 2123, 2125, 2126, 2144, 2145, 2146, 2148, 2149, 2175, 2190, 2191, 2239, 2240, 2242, 2243, 2274, 2275, 2277, 2278 systemic sclerosis 560, 566, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 584, 586, 588, 590, 593, 596, 597, 598, 599, 603, 604, 605, 606, 607, 609, 610, 611, 613, 614, 615, 616, 619, 670, 671, 673, 724, 725, 726, 728, 824, 829, 1201, 1204, 1206, 1207, 1208, 1211, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 372 2010 Program Book
1226, 1227, 1229, 1230, 1231, 1233, 1234, 1235, 1236, 1237, 1239, 1346, 1347, 1348, 1587, 1623, 1624, 1627, 1704, 1987, 1988, 1989, 1990, 1991, 1994, 1997, 1998, 1999, 2000, 2001, 2002, 2004, 2005, 2007, 2008, 2086, 2192, 2193, 2196, 2226, 2247 systems biology 733 T cell anergy 1264 T cell help 867 T cell receptor revision 1272 T cells 38, 265, 275, 287, 350, 370, 372, 432, 434, 435, 437, 442, 462, 488, 497, 505, 507, 636, 740, 825, 830, 846, 863, 867, 909, 935, 1069, 1079, 1090, 1125, 1141, 1150, 1185, 1187, 1196, 1241, 1242, 1244, 1245, 1248, 1249, 1250, 1251, 1254, 1255, 1256, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1274, 1278, 1446, 1499, 1524, 1525, 1724, 1801, 1838, 1843, 1900, 1903, 1919, 1967, 1989, 2004, 2126, 2127, 2128, 2129, 2130, 2188, 2190, 2191, 2232, 2275 T follicular helper cell 432, 1141 T helper cells 1992 T helper subsets 635 TFH 1250 T-5224 280, 1467 TACI 2178 tadalafil 2086 tai chi 690 TAK1 1535 Takayasu 1275, 1279, 1286, 1287, 1290, 1291, 1295, 1313, 1315, 2198 Takayasu’s arteritis 1282, 1283 targeted resequencing 2146 TASK2 1255 TCZ 1434, 1840 team-based learning 46, 1432 technology 1334 telangiectases 1234 temporal arteritis 1302, 2044 temporal artery biopsy 1311 temporomandibular joint 213, 218, 228 tender 1434 tendinopathies 106 tendonitis 898 tendonitis/bursitis 2212 tenocytes 106 teratozoospermia 513 teriparatide 967, 980 testicular function 513 testing 1543, 1561 TGF-beta 244, 442, 489 Th1 and Th17 1903 Th1, Th2, Th17 cells 435 T Th17 265, 275, 370, 715, 1241, 1249, 1274, 1838, 2130 Th17 cells 1970, 2129 Th9 1241 thalidomide 1657 theophylline 149 therapeutic approaches 1700 therapeutic delay 558 therapeutic targets 733 therapy 1683, 1831, 2048 therapy monitoring 138 therapy response 83 thermography 1439 thoracic manipulation 2060 thrombin 604 thrombin generation 1 thrombosis 1, 2, 3, 5, 6, 8, 13, 14, 374, 460, 482, 906, 1243, 1357, 1602, 2255 thrombospondins 1991 thymic negative selection 1260 thyroid 1029, 1038 thyroid nodule 1038 tight control 380, 1104, 1753 TIM-2 1731 TIM-3 372 tissue factor 2254 tissue inhibitor <strong>of</strong> metalloproteinase 3 (TIMP3) 1478 tissue regeneration 1380 tissue remodelling 629 tissue targeting 852 tlda 1986 TLR2 858 TLR-2 ligand 267 TLR4 1495, 1501, 1535, 1730 TLR7 1410 TNF 1695 TNF antagonists 216 TNF genes polymorphism 217 TNF inhibitor 419 TNF-alpha 371 TNFRSF1A gene 837 tobacco 1551 tobacco use 470, 562, 661, 1035, 1070, 1093, 1152, 1546, 1850 tocilizumab 56, 120, 237, 329, 373, 378, 384, 399, 411, 701, 745, 759, 1115, 1138, 1411, 1434, 1788, 1793, 1797, 1800, 1808, 1809, 1819, 1820, 1823, 1839, 1840, 2262 tolerance 1116, 1717 tolerogenic dendritic cells 1715 toll-like receptor 2 16, 857 toll-like receptor 4 713 toll-like receptor 7 856, 862, 1584 toll-like receptor 9 856, 862 toll-like receptors (TLR) 424, 1296, 1391, 1501, 1883, 1993, 2023 tophaceous 2152 tophi 157 topical 944 total elbow replacement 1080 total joint replacement 174, 196, 1539, 1576, 2053, 2054, 2090, 2136, 2137 total knee arthroplasty 171 trabecular morphometry 709 traditional cardiovascular risk factors 1067 TRAIL 1527 tranilast 160 transcription factor 38, 258, 507, 616, 1251, 1259, 1469, 1487, 1508, 1522, 1526, 1724, 2177, 2274 transcriptional targeting 1733 transcriptomics 1422, 1981 trans-ethnic mapping 1595 transforming growth factor 600, 602, 617, 673, 674, 1241, 1997 transition 211, 1340 transition care 1008, 1409 translational research 607 transmigration 1420 transplantation 704, 713, 874, 907, 918, 1143, 1161, 2104 transracial mapping 2274 transverse myelitis 1174 traps 905 trauma 1551 treatment 117, 196, 218, 676, 705, 902, 1306, 1315, 1380, 1543, 1561, 1670, 1675, 2273 treatment decision 82, 1899 treatment preference 1875 treatment protocols 1702 treatment response 453, 828, 1452 treatment strategies 311 Treg 370, 1196 Treg activator 1125 Treg cells 2129 treprostinil 1201, 1222 treprostinil diethanolamine 597 trial 1892 trimethoprim-sulphamethoxazole 472 triple therapy 1368 tuberculosis 376, 404, 699, 768, 782, 890, 908, 997, 1012, 1310, 1941 tuberculosis skin test 756, 782 tumor necrosis factor (TNF) 62, 88, 241, 249, 345, 356, 406, 712, 897, 1020, 1133, 1198, 1442, 1444, 1487, 1530, 1532, 1534, 1607, 1643, 1680, 1841, 1942, 1958 tumor necrosis factor receptor associated periodic syndrome 837 twin study 877 abstract KEYWORD INDEX 2010 Program Book 373
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364: cost-utility 759, 1539 couples 1324
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367 and 368: impact 1063, 1325 inactive disease
- Page 369 and 370: methylation 826, 1253, 1489 methylt
- Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
- Page 373: 1599, 1600, 1603, 1605, 1606, 1609,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)
Change language